AGP Picks
View all

Exploring the business and economy news of Liechtenstein

Provided by AGP

AGP Executive Report

Last update: 5 hours ago

M&A in Pharma: SERB Pharmaceuticals is buying Idefirix® (imlifidase) rights from Hansa Biopharma for €115m, securing exclusive EU/UK/Switzerland/Norway/Liechtenstein and MENA development and commercialisation for a kidney-transplant desensitisation drug aimed at highly sensitised patients. Bilateral Business Push: PM Narendra Modi’s Norway visit is turning into a trade-and-energy sprint: leaders agreed a “Green Strategic Partnership” on clean energy, climate resilience, blue economy and green shipping, while also pointing to the India–EFTA TEPA deal (including Liechtenstein) as a blueprint for deeper investment and market access. Regulatory Friction Watch: EU steel tariffs are back in the spotlight after Brussels rejected Swiss criticism, arguing the EU can act autonomously outside the Swiss-EU stabilisation package. Local Execution Theme: Norwegian firms told Modi to fix “ground level” regulatory bottlenecks to make approvals faster. Cross-border Mobility: UK airports will expand e-gates for children aged eight and nine from July 8, potentially easing summer queues for families.

Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.

YouTube video thumbnail: Trust the Source. Trust the News.
Play

Video Title


Perspectify logo Perspectify News

Learn about labels.

Labels
Left-wing Center-left Neutral Public Broadcaster Gov't Institution Center-right Right-wing Pro-Government Gov't Propaganda Indeterminate
filter

Filter

Source Label Filters

All labels are selected. Deselect any labels you want to hide from your feed.

Labels:

Left-wing
Center-left
Neutral
Public Broadcaster
Gov't Institution
Center-right
Right-wing
Pro-Government
Gov't Propaganda
Indeterminate
Address ‘ground level challenges’, ease regulatory frameworks: Norwegian businesses tell Modi

Address ‘ground level challenges’, ease regulatory frameworks: Norwegian businesses tell Modi


fallback image
7 hours ago

SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million

GlobeNewswire, Inc.

fallback image
May. 7, 2026

Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026

GlobeNewswire, Inc.

fallback image
May. 5, 2026

CEO Insight’s Investors Guide Examines Evolving Investment Strategies Across Global Financial Markets

EIN Presswire

fallback image
Apr. 16, 2026

Clear Street Expands European Market Access with MiFID II License in the Netherlands

GlobeNewswire, Inc.

fallback image
Mar. 30, 2026

Dental Laboratories Market Set to Reach USD 13.09 Billion by 2030 | MarketsandMarkets™

GlobeNewswire, Inc.

fallback image
Mar. 30, 2026

4BIO Capital strengthens investment leadership with appointment of Therese Liechtenstein as Partner and Tetsu Maruyama as Venture Partner

GlobeNewswire, Inc.

More press releases

Video Stories

YouTube video thumbnail: 'Dream, Work Boldly': Bulgaria's First Eurovision Winner to Fans
Play
'Dream, Work Boldly': Bulgaria's First Eurovision Winner to Fans
YouTube video thumbnail: Russia and Ukraine Exchange Overnight Drone Attacks
Play
Russia and Ukraine Exchange Overnight Drone Attacks
Discover Affinity Group Publishing
YouTube video thumbnail: Von der Leyen Lauds 'Dynamic New Era' in EU-India Relations as Modi Visits Sweden
Play
Von der Leyen Lauds 'Dynamic New Era' in EU-India Relations as Modi Visits Sweden
YouTube video thumbnail: Why LGBTQ+ Hate Crimes Are Surging in Germany
Play
Why LGBTQ+ Hate Crimes Are Surging in Germany

Video Title

Sign up for:

Liechtenstein Business Focus

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

globe

Explore More

Share us

on your social networks:

Sign up for:

Liechtenstein Business Focus

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.